Pacira reports inducement grants under Nasdaq listing rule

Pacira (PCRX) BioSciences announced the granting of inducement awards on June 3, 2025 to 19 new employees under Pacira’s Amended and Restated 2014 Inducement Plan as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors without stockholder approval. 11 employees received stock options to purchase an aggregate of 26,700 shares of Pacira common stock and 19 employees received restricted stock units for an aggregate of 41,600 shares of Pacira common stock. The stock options have a 10-year term and a four-year vesting schedule with 25 percent of the underlying shares vesting on the first anniversary of the recipient’s first day of employment and in successive equal quarterly installments over the 36 months thereafter. The stock options have an exercise price of $26.40 per share, the closing trading price of Pacira common stock on the Nasdaq Global Select Market on the date of grant. Each restricted stock unit represents the contingent right to receive one share of Pacira common stock and the restricted stock unit awards vest annually in four equal installments beginning on June 1, 2026. Vesting of the equity awards is subject to the employee’s continued employment with Pacira. Each equity award is also subject to the terms and conditions of an award agreement.